|Articles|May 1, 2003

A refreshing way to distinguish allergy from infection?

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children | Image Credit: © Jacob Lund - stock.adobe.com

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children

ByMorgan Ebert, Executive Editor

September 2nd 2026

New evidence review finds flu, RSV and COVID-19 vaccines continue protecting infants and children from severe illness | Image Credit: © angellodeco - stock.adobe.com.

New evidence review finds flu, RSV and COVID-19 vaccines continue protecting infants and children from severe illness

ByMorgan Ebert, Executive Editor

September 2nd 2026

AAP expands RSV immunization recommendations for high-risk children | Image Credit: © Sukjai Photo - stock.adobe.com

AAP expands RSV immunization recommendations for high-risk children

ByMorgan Ebert, Executive Editor

September 2nd 2026

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak | Image Credit: © Tada Images - stock.adobe.com.

CDC declares Nara Organics infant botulism outbreak over as genetic testing links it to 2025 ByHeart outbreak

ByMorgan Ebert, Executive Editor

August 27th 2026

What pediatricians should know for the upcoming respiratory virus season

What pediatricians should know for the upcoming respiratory virus season

ByLori Handy, MD, MSCE

August 27th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

AAP expands RSV immunization recommendations for high-risk children

PCOS to PMOS: A long-awaited change

From primary care to specialist: Managing PMOS and insulin resistance

Diagnosing PMOS in adolescents: Criteria, ultrasound limits, and red flags

AAP recommends 2026-2027 COVID-19 vaccine for all infants 6 to 23 months and at-risk older children